دورية أكاديمية
Risk-adjusted therapy for pediatric non-T cell ALL improves outcomes for standard risk patients: results of JACLS ALL-02
| العنوان: | Risk-adjusted therapy for pediatric non-T cell ALL improves outcomes for standard risk patients: results of JACLS ALL-02 |
|---|---|
| المؤلفون: | Hasegawa, Daiichiro, Imamura, Toshihiko, Yumura-Yagi, Keiko, Takahashi, Yoshihiro, Usami, Ikuya, Suenobu, So-Ichi, Nishimura, Shinichiro, Suzuki, Nobuhiro, Hashii, Yoshiko, Deguchi, Takao, Moriya-Saito, Akiko, Kato, Koji, Kosaka, Yoshiyuki, Hirayama, Masahiro, Iguchi, Akihiro, Kawasaki, Hirohide, Hori, Hiroki, Sato, Atsushi, Kudoh, Tooru, Nakahata, Tatsutoshi, Oda, Megumi, Hara, Junichi, Horibe, Keizo |
| المساهمون: | 中畑, 龍俊 |
| بيانات النشر: | Springer Nature |
| سنة النشر: | 2020 |
| المجموعة: | Kyoto University Research Information Repository (KURENAI) / 京都大学学術情報リポジトリ |
| الوصف: | This study was a second multicenter trial on childhood ALL by the Japan Childhood Leukemia Study Group (JACLS) to improve outcomes in non-T ALL. Between April 2002 and March 2008, 1138 children with non-T ALL were enrolled in the JACLS ALL-02 trial. Patients were stratified into three groups using age, white blood cell count, unfavorable genetic abnormalities, and treatment response: standard risk (SR), high risk (HR), and extremely high risk (ER). Prophylactic cranial radiation therapy (PCRT) was abolished except for CNS leukemia. Four-year event-free survival (4yr-EFS) and 4-year overall survival (4yr-OS) rates for all patients were 85.4% ± 1.1% and 91.2% ± 0.9%, respectively. Risk-adjusted therapy resulted in 4yr-EFS rates of 90.4% ± 1.4% for SR, 84.9% ± 1.6% for HR, and 66.5% ± 4.0% for ER. Based on NCI risk classification, 4yr-EFS rates were 88.2% in NCI-SR and 76.4% in NCI-HR patients, respectively. Compared to previous trial ALL-97, 4yr-EFS of NCI-SR patients was significantly improved (88.2% vs 81.2%, log rank p = 0.0004). The 4-year cumulative incidence of isolated (0.9%) and total (1.5%) CNS relapse were significantly lower than those reported previously. In conclusion, improved EFS in NCI-SR patients and abolish of PCRT was achieved in ALL-02. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2044-5385 32107374 |
| العلاقة: | http://hdl.handle.net/2433/261942Test; Blood cancer journal; 10; 23 |
| الإتاحة: | http://hdl.handle.net/2433/261942Test |
| حقوق: | © The Author(s) 2020 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0Test/. |
| رقم الانضمام: | edsbas.344722D7 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 20445385 32107374 |
|---|